West Pharmaceutical Services Inc. (WST)
WST trades on NYSE in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/105770/000010577026000010/0000105770-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | WST on NYSE |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000105770 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | PA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.1B |
| Net income | $493.7M |
| Operating income | $584.9M |
| Net margin | 16.1% |
| Operating margin | 19.0% |
| Revenue growth | +6.3% |
| Cash | $791.3M |
| Total assets | $4.3B |
| P/E (computed) | 59.0× |
| P/S (computed) | 9.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $464.1M cash; operating cash flow $163.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 69,661,036 (2026-10-21); 71,943,412 a year earlier; 73,989,670 three years earlier. | Cover page 2026-10-21 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $6.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $874.5M | $214.0M | $189.5M | $464.1M | $202.9M | $3.4B | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $872.3M | $154.0M | $124.0M | $435.8M | $202.9M | $3.3B | 10-Q 2026-07-23 |
| Q1 2026 2026-03-31 | $844.9M | $138.8M | $89.9M | $521.4M | $202.8M | $3.2B | 10-Q 2026-04-23 |
| Q4 2025 2025-12-31 | $805.0M | $132.1M | $251.1M | $791.3M | $202.8M | $3.1B | 10-K 2026-02-17 |
| Q3 2025 2025-09-30 | $804.6M | $140.0M | $197.2M | $628.5M | $202.7M | $3.0B | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $766.5M | $131.8M | $177.1M | $509.7M | $202.6M | $3.0B | 10-Q 2026-07-23 |
| Q1 2025 2025-03-31 | $698.0M | $89.8M | $129.4M | $404.2M | $202.6M | $2.9B | 10-Q 2026-04-23 |
| Q4 2024 2024-12-31 | $748.8M | $130.1M | $190.1M | $484.6M | $202.6M | $2.9B | 10-K 2026-02-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 10-K | 2026-02-17 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-03-12 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.2% |
| 1 month | +12.0% |
| 3 months | +20.3% |
| Year to date | +51.3% |
| 1 year | +56.2% |
| From 52-week high | -0.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DXCM | DexCom Inc. | $81.61 | -2.06% | $30.4B |
| RMD | ResMed Inc. | $238.19 | -0.56% | $33.5B |
| MDLN | Medline Inc. | $39.17 | -0.76% | $51.5B |
| SOLV | Solventum Corporation | $88.65 | -0.48% | $15.0B |
| GKOS | Glaukos Corporation | $244.88 | -0.34% | $14.5B |
| BDX | Becton Dickinson and Company | $216.47 | -0.72% | $59.0B |
| BSX | Boston Scientific Corporation | $43.69 | -1.47% | $63.3B |
| BAX | Baxter International Inc. | $25.54 | -1.05% | $13.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier